All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.

More information on our cookie policy.

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
  • Special reports
    • Artificial intelligence
    • Coronavirus
    • IVDs on the rise
    • Top Biopharma Trends of 2021
    • Top Med-tech Trends of 2021
    • Premium reports
      • BioWorld Financings Reports
      • Disease Incidence & Prevalence Summaries

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Wednesday, July 6, 2022
Home » Topics » Newco news

Newco news
Newco news RSS Feed RSS

Clarity Pharmaceuticals sarcophagine (SAR) technology platform
Newco news

Radiopharma Clarity touts advantages of its targeted copper theranostics

July 6, 2022
By Tamra Sami
No Comments
Clarity Pharmaceuticals Ltd. is progressing three of its targeted copper theranostics through the clinic that are based on its sarcophagine technology that securely holds copper isotopes inside a cage-like structure, called a chelator. The SAR technology allows a unique pairing of copper isotopes, copper-64  and copper-67, for both cancer diagnosis and therapy.
Read More
Newco news

Old drug, new tricks: Aneurotech taking well-known antipsychotic into US depression trial

July 5, 2022
By Nuala Moran
No Comments
After filing patents on a decades-old antipsychotic, Aneurotech BV is laying plans for a U.S. phase IIIb trial of the drug as an adjunctive therapy in major depressive disorder. The study will assess the effects of ANT-01, a low dose of pipamperone, a selective antagonist of both the serotonin 5-HT2A and D4 dopamine receptors, which has been on the market in some countries in Europe and elsewhere for more than 40 years.
Read More
Wensheng Wei, founder, Therorna
Newco news

Chinese biotech Therorna completes $42M series A to develop circRNA COVID-19 vaccines

June 28, 2022
By Tamra Sami
No Comments
Chinese biotech company Therorna Inc. completed a $42 million series A round to develop its circular RNA (circRNA) vaccines and therapies.
Read More
Hand holding dollar sign
Newco news

Alladapt’s goal is to help food allergy sufferers adapt

June 24, 2022
By Lee Landenberger
No Comments
The only way to avoid food allergies right now is to stay away from whatever triggers them and, at best, grab some rescue epinephrine in case there’s trouble. Peanut allergies have an FDA-approved treatment, but the remainder of the troublemakers don’t have any therapies. Hoping to change that, Alladapt Immunotherapeutics Inc. closed a $119 million financing to develop its food allergy treatments. The Menlo Park, Calif.-based company’s lead candidate is ADP-101, an oral immunotherapy that is in a phase I/II trial and an open-label extension study of children and adults.
Read More
Newco news

Carbon Biosciences takes aim at cystic fibrosis, launching with $38M toward next-gen gene therapy

June 24, 2022
By Richard Staines
No Comments
Although there has been huge progress in treatment of cystic fibrosis over the last decade, with Vertex Pharmaceuticals Inc. becoming the first to address the underlying cause of the disease with its Kalydeco (ivacaftor), approved in 2012, there are still many patients who aren’t eligible for treatment.
Read More
Wensheng Wei, founder, Therorna
Newco news

Chinese biotech Therorna completes $42M series A to develop circRNA COVID-19 vaccines

June 23, 2022
By Tamra Sami
No Comments
Chinese biotech company Therorna Inc. completed a $42 million series A round to develop its circular RNA (circRNA) vaccines and therapies.
Read More
Coins and seedling
Newco news

Ratio Therapeutics emerges with $20M financing, taking mathematical approach to radiopharmaceuticals

June 20, 2022
By Richard Staines
No Comments
In the last decade, Bayer AG and Novartis AG have shown that radiopharmaceutical technology can produce marketable drugs, with Xofigo (radium-223 dichloride) and Lutathera (lutetium [177Lu] oxodotreotide), respectively approved for prostate cancer and neuroendocrine tumors.
Read More
Heart and kidneys
Newco news

Vectus shows lead candidate reverses heart, kidney fibrosis

June 16, 2022
By Tamra Sami
No Comments
From 20 years of research on metabolic change as a result of salt intake, Karen Duggan discovered in 2003 that a naturally occurring molecule in the human body, native vasoactive intestinal peptide (VIP), was capable of reversing fibrosis caused by hypertension and other chronic diseases such as diabetes. From that discovery, Vectus Biosystems Ltd. was founded, and the company has developed a new class of mimetic drug candidates and a drug library based on VIP.
Read More
Antibody-drug conjugate
Newco news

Profoundbio completes $70M series A round to advance ADC programs to the clinic

June 14, 2022
By Tamra Sami
No Comments
Profoundbio Inc. closed a $70 million series A financing round that will see it advance its two lead antibody-drug conjugate (ADC) programs to the clinic. The Suzhou, China, and Woodinville, Wash.-based company has raised a total of more than $138 million in the past two years.
Read More
Antibody-drug conjugate
Newco news

Profoundbio completes $70M series A round to advance ADC programs to the clinic

June 9, 2022
By Tamra Sami
No Comments
Profoundbio Inc. closed a $70 million series A financing round that will see it advance its two lead antibody-drug conjugate (ADC) programs to the clinic. The Suzhou, China, and Woodinville, Wash.-based company has raised a total of more than $138 million in the past two years.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 29 30 Next

Popular Stories

  • Free access to BioWorld coronavirus articles

    BioWorld

    The articles in this collection are from BioWorld’s ongoing coverage of the COVID-19 coronavirus outbreak. Note that we have added three critical tables which are...

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 6, 2022.
  • Novavax-COVID-19-vaccine-vial

    Novavax vaccine shows its chops

    BioWorld
    Given that Novavax Inc.’s COVID-19 vaccine will be a latecomer to the U.S. scene if it gets FDA authorization, it’s been cast in a supporting role to the lead...
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech's briefs for July 6.
  • Blood sample, DNA

    Biomarin outlines pricing strategy for costly hemophilia A gene therapy after backing from European regulators

    BioWorld
    The first gene therapy to treat severe hemophilia A was among the drugs recommended for European approval by regulators from the EMA’s CHMP at its monthly...
black cortellis ad

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.

Subscribe
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Archives
    • Today's news
    • Search BioWorld Science
    • About
  • More
    • About
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
Follow Us

Copyright ©2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing